LJ
Therapeutic Areas
CSPC Pharmaceutical Group Limited Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Envafolimab (CIPTRAMON) | MSI-H/dMMR solid tumors | Approved |
| DPP-1 Inhibitor (CSPC-2231) | Acute exacerbation of COPD, Bronchiectasis | Phase III |
| IL-17A/F Inhibitor (CSPC-2232) | Psoriasis | Phase III |
| ADC Candidate (CSPC-5018) | Advanced solid tumors | Phase I/II |
| Nectin-4 ADC (CSPC-5092) | Advanced solid tumors | Phase I |
| TROP2 ADC (CSPC-6024) | Advanced solid tumors | Phase I |
| Claudin 18.2 ADC (CSPC-5902) | Advanced solid tumors | Phase I |